Quanterix's Simoa® Technology Drives Advances in Alzheimer's Disease Research Presented at 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Author's Avatar
Dec 05, 2022

Quanterix+Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th+Clinical+Trials+on+Alzheimer%26rsquo%3Bs+Disease+%28CTAD%29+conference held in San Francisco, CA from November 29 to December 2, 2022.